Heart failure and oncologic treatment
DOI:
https://doi.org/10.6016/ZdravVestn.2934Keywords:
myocardial injury, anthracyclins, heart failure prevention, heart failure treatmentAbstract
Heart failure after oncological treatment is a hot topic in oncology as well as in cardiology and it demands quick diagnostic and therapeutic interventions. The most commonly used classification of myocardial damage is still type I (anthracycline-like) and type II (trastuzumab-like) myocardial injury. Radiotherapy is also a significant contributor to cardiotoxicity in onco-logic patients. The European Society of Cardiology has published guidelines regarding surveillance and follow up of such patients, the golden standard of imaging techniques being echocardiography. Other imaging techniques and laboratory modalities could be used but are not widely available. This year’s recommendations of the European Society of Medical Oncology advise considering the use of cardioprotective medications before and during therapy in individuals with known cardiovascular risk factors. However, individual approach to every patient is of paramount importance.
Downloads
References
1. Rak v Sloveniji 2015. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije; 2016.
2. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al.; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-801.
DOI: 10.1093/eurheartj/ehw211
PMID: 27567406
3. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23(13):2900-2.
DOI: 10.1200/JCO.2005.05.827
PMID: 15860848
4. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911-39.
DOI: 10.1016/j.echo.2014.07.012
PMID: 25172399
5. Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. Circ Heart Fail. 2016;9(1):e002661.
DOI: 10.1161/CIRCHEARTFAILURE.115.002661
PMID: 26747861
6. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-90.
DOI: 10.1016/j.annonc.2019.10.023
PMID: 31959335
7. Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839-46.
DOI: 10.1158/0008-5472.CAN-07-1649
PMID: 17875725
8. Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(13):1415-21.
DOI: 10.1200/JCO.2011.34.8987
PMID: 22124095
9. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-8.
DOI: 10.1161/CIRCULATIONAHA.114.013777
PMID: 25948538
10. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266(12):1672-7.
DOI: 10.1001/jama.1991.03470120074036
PMID: 1886191
11. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213-20.
DOI: 10.1016/j.jacc.2009.03.095
PMID: 20117401
12. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al.; Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104(17):1293-305.
DOI: 10.1093/jnci/djs317
PMID: 22949432
13. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4(4):CD006243.
DOI: 10.1002/14651858.CD006243.pub2
PMID: 22513938
14. Žgajnar J. Smernice diagnostike in zdravljenja raka dojk. Ljubljana: Onkološki inštitut Ljubljana; 2014.
15. Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol. 2012;23(3):791-800.
DOI: 10.1093/annonc/mdr294
PMID: 21665955
16. Krop IE, Suter TM, Dang CT, Dirix L, Romieu G, Zamagni C, et al. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. J Clin Oncol. 2015;33(10):1136-42.
DOI: 10.1200/JCO.2014.58.7782
PMID: 25713436
17. Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial. J Clin Oncol. 2016;34(10):1034-42.
DOI: 10.1200/JCO.2015.62.1797
PMID: 26598744
18. Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2015;94(2):228-37.
DOI: 10.1016/j.critrevonc.2014.12.008
PMID: 25577572
19. Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol. 2013;61(23):2319-28.
DOI: 10.1016/j.jacc.2013.01.090
PMID: 23583253
20. Filopei J, Frishman W. Radiation-induced heart disease. Cardiol Rev. 2012;20(4):184-8.
DOI: 10.1097/CRD.0b013e3182431c23
PMID: 22314140
21. van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007-17.
DOI: 10.1001/jamainternmed.2015.1180
PMID: 25915855
22. Matthews A, Stanway S, Farmer RE, Strongman H, Thomas S, Lyon AR, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ. 2018;363:k3845.
DOI: 10.1136/bmj.k3845
PMID: 30297439
23. Haanen J, Carbonnel F, Robert C, Kerr K, Peters S, Larkin J, et al. Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2017;28(4):iv119-42.
DOI: 10.1093/annonc/mdx225
24. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749-55.
DOI: 10.1056/NEJMoa1609214
PMID: 27806233
25. Tadokoro T, Keshino E, Makiyama A, Sasaguri T, Ohshima K, Katano H, et al. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ Heart Fail. 2016;9(10):e003514.
DOI: 10.1161/CIRCHEARTFAILURE.116.003514
PMID: 27650418
26. Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3(1):11.
DOI: 10.1186/s40425-015-0057-1
PMID: 25901283
27. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr. 2013;26(5):493-8.
DOI: 10.1016/j.echo.2013.02.008
PMID: 23562088
28. Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging. 2013;6(6):1080-91.
DOI: 10.1161/CIRCIMAGING.113.000899
PMID: 24254478
29. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al.; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(7):vii155-66.
DOI: 10.1093/annonc/mds293
PMID: 22997448
30. Hamo CE, Bloom MW, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. Circ Heart Fail. 2016;9(2):e002843.
DOI: 10.1161/CIRCHEARTFAILURE.115.002843
PMID: 26839395
31. Cardinale D, Bacchiani G, Beggiato M, Colombo A, Cipolla CM. Strategies to prevent and treat cardiovascular risk in cancer patients. Semin Oncol. 2013;40(2):186-98.
DOI: 10.1053/j.seminoncol.2013.01.008
PMID: 23540744
32. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749-54.
DOI: 10.1161/01.CIR.0000130926.51766.CC
PMID: 15148277
33. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910-6.
DOI: 10.1200/JCO.2009.27.3615
PMID: 20679614
34. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603.
DOI: 10.1161/CIRCIMAGING.112.973321
PMID: 22744937
35. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258-62.
DOI: 10.1016/j.jacc.2006.07.052
PMID: 17161256
36. Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013;167(5):2306-10.
DOI: 10.1016/j.ijcard.2012.06.023
PMID: 22727976
37. Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6(3):420-6.
DOI: 10.1161/CIRCHEARTFAILURE.112.000055
PMID: 23425978
38. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355-62.
DOI: 10.1016/j.jacc.2013.02.072
PMID: 23583763
39. Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104(11):2492-8.
DOI: 10.1002/cncr.21478
PMID: 16247790
40. Cadeddu C, Piras A, Mantovani G, Deidda M, Dessì M, Madeddu C, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160(3):487.e1-7.
DOI: 10.1016/j.ahj.2010.05.037
PMID: 20826257
41. Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17(1):81-9.
DOI: 10.1002/ejhf.196
PMID: 25410653
42. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474-81.
DOI: 10.1161/CIRCULATIONAHA.106.635144
PMID: 17101852
43. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60(23):2384-90.
DOI: 10.1016/j.jacc.2012.07.067
PMID: 23141499
44. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200.
DOI: 10.1093/eurheartj/ehw128
PMID: 27206819
45. Fadol AP. Management of Chemotherapy-Induced Left Ventricular Dysfunction and Heart Failure in Patients With Cancer While Undergoing Cancer Treatment: the MD Anderson Practice. Front Cardiovasc Med. 2018;5:24.
DOI: 10.3389/fcvm.2018.00024
PMID: 29644219
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
